Health Care • Biotechnology: Pharmaceutical Preparations
$14.32 ▲ +0.12
(+0.81%)
MKT CAP: $209.1M • VOL: 130.8K
52W L $5 52W H $42
ROARABLE / RQD
D • 44/100
PIOTROSKI
3 / 9
KRRO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $6.4M | $2.3M | $0 |
| YoY Revenue Growth % | +181.5% | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$121.9M | -$91.9M | -$84.5M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$117.3M | -$83.6M | -$81.2M |
| EBITDA (Normalized) | -$121.4M | -$77.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$78.6M | -$60.1M | -$67.3M |
| Capital Expenditures (CapEx) | $518.0K | $17.9M | — |
| Free Cash Flow (FCF) | -$79.1M | -$78.0M | -$67.3M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $21.8M | $55.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $51.4M | $160.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR KRRO.